Clinical correlates of vitamin D deficiency in established psychosis by Lally, J et al.
RESEARCH ARTICLE Open Access
Clinical correlates of vitamin D
deficiency in established psychosis
J. Lally1,2, P. Gardner-Sood1, M. Firdosi3, C. Iyegbe1, B. Stubbs4,5, K. Greenwood6, R. Murray7, S. Smith7, O. Howes1,8
and F. Gaughran1,2*
Abstract
Background: Suboptimal vitamin D levels have been identified in populations with psychotic disorders.
We sought to explore the relationship between vitamin D deficiency, clinical characteristics and cardiovascular
disease risk factors among people with established psychosis.
Methods: Vitamin D levels were measured in 324 community dwelling individuals in England with established
psychotic disorders, along with measures of mental health, cardiovascular risk and lifestyle choices. Vitamin D
deficiency was defined as serum 25-hydroxyvitamin D (25-OHD) levels below 10 ng/ml (equivalent to
<25 nmol/L) and “sufficient” Vitamin D as above 30 ng/ml (>50 nmol/L).
Results: The mean 25-OHD serum level was 12.4 (SD 7.3) ng/ml, (range 4.0-51.7 ng/ml). Forty nine percent (n = 158)
were vitamin D deficient, with only 14 % (n = 45) meeting criteria for sufficiency. Accounting for age, gender, ethnicity
and season of sampling, serum 25-OHD levels were negatively correlated with waist circumference (r = −0.220, p <
0.002), triglycerides (r = −0.160, p = 0.024), total cholesterol (r = −0.144, p = 0.043), fasting glucose (r = −0.191, p = 0.007),
HbA1c (r = −0.183, p = 0.01), and serum CRP levels (r = −0.211, p = 0.003) and were linked to the presence of metabolic
syndrome.
Conclusions: This is the largest cross sectional study of serum 25-OHD levels in community dwelling individuals with
established psychosis, indicating a high level of vitamin D deficiency. Lower vitamin D levels are associated with
increased cardiovascular disease risk factors and in particular metabolic syndrome. Further research is needed to define
appropriate protocols for vitamin D testing and supplementation in practice to see if this can improve cardiovascular
disease risk.
Trial registration: ISRCTN number is ISRCTN58667926 Date of registration: 23/04/2010
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Background
Vitamin D levels are sub-optimal in people with schizo-
phrenia and other psychotic disorders [1, 2], being lower
than matched controls even from the first episode of
psychosis [3]. Lifestyle and physical health factors associ-
ated with low vitamin D, such as smoking [4], increased
body mass index [5], inactivity, and social withdrawal
(likely resulting in deceased sunlight exposure), are all
more frequent in people with psychosis.
In the general population, research has demonstrated
that individuals with heart failure, hypertension, stroke,
and other cardiovascular diseases (CVD) tend to have
lower vitamin D levels [6]. Moreover, type 2 diabetes
mellitus is more prevalent among people with low vita-
min D levels and those who spend less time in the sun
[7]. In addition there is an inverse relationship between
vitamin D levels and hypertension, obesity and waist cir-
cumference [8], all key components of metabolic syn-
drome (MetS). Recent research has demonstrated that
people with psychosis demonstrate high levels of
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cardiovascular risk, MetS [9, 10] and type 2 diabetes
mellitus [11] which are leading contributors to prema-
ture mortality in this population [12]. There is accumu-
lating evidence that vitamin D deficiency may be
associated with inflammatory cytokines [13] which could
explain this relationship. However, to our knowledge,
only one other study has investigated this in people with
psychosis [14].
Previous studies of vitamin D deficiency in commu-
nity patients with psychosis have had small sample
sizes [15, 16] and few have examined the relationship
between vitamin D status and clinical domains of an
individual’s illness [15, 17]. In particular, no author
has fully explored the relationship between vitamin D
and cardiovascular disease risk in people with estab-
lished psychosis, despite this relationship being ob-
served in the general population [18]. Cardiovascular
disease is the leading cause of premature mortality in
this population [19], if vitamin D is related to cardio-
vascular disease risk in people with established psych-
osis, this may either be amenable to change or be a
marker of change, and could assist in collaborative ef-
forts to reduce cardiovascular disease in this popula-
tion. Importantly, there have been no previous studies
reporting the influence of lifestyle factors and dur-
ation of time spent outdoors on vitamin D levels in
established psychosis.
Aims
We set out to determine the prevalence of vitamin D de-
ficiency in a cohort of community patients with estab-
lished psychotic illnesses and ascertain the relationship
between vitamin D status and specific clinical features
and in particular cardiovascular risk in psychosis.
Methods
Study design
This is a cross-sectional study of a random sample of
people with established psychosis, recruited at baseline
to the NIHR funded Improving Physical health and re-
ducing substance use in Psychosis (IMPaCT) rando-
mised controlled trial (RCT) [20].
Setting
The study took place within English community mental
health teams (CMHTs). Potential participants were iden-
tified through their community mental health team care-
coordinator. All care-coordinators in participating
CMHTs were approached in random sequence and in-
vited to participate. Patients on each participating care
coordinator’s caseload, meeting the inclusion criteria,
were likewise approached in a random order and se-
quentially invited to participate.
Clinical and sociodemographic variables
Sociodemographic and clinical data were collected includ-
ing gender, age, ethnicity, diagnosis and duration of illness
(self-report measure). Diagnoses were based on ICD-10
diagnostic criteria and extracted from the documented
diagnosis in the clinical notes at study recruitment. All
data were collected at the same timepoint for each indi-
vidual patient. Participants’ mental health status was mea-
sured using the Positive And Negative Syndrome Scale
(PANSS) [21], Global Assessment of Functioning (GAF)
[22] and the Montgomery Asberg Depression Rating Scale
(MADRS) [23]. The EuroQoL-5 dimension (EQ-5D) [24]
was used to measure health related quality of life
(HRQoL) in participants. Both EQ-5 D index scores and
EQ-5 D visual analogue scale scores were recorded.
Current smoking was recorded using the Nicotine De-
pendence Questionnaire [25] and alcohol use by the Alco-
hol Use Disorders Identification Test (AUDIT) [26]. The
International Physical Activity Questionnaire (IPAQ) was
used as a measure of physical activity [27]. The IPAQ
measures the intensity of physical activity (high, moderate,
low) and the duration of walking physical activities over
the previous week and is a valid tool for use in this popu-
lation [28].
All total scores from the scales were derived from the
individual scale items. If any of the individual items were
missing, then the total score was treated as missing.
Vitamin D
Levels of Vitamin D (serum 25-hydroxyvitamin D (25-
OHD)) were determined by chemiluminescence im-
munoassay (DiaSorin, S.P.A. Saluggia (Vercelli), Italy).
Vitamin D deficiency was defined as 25-OHD levels
below 10 ng/ml (equivalent to <25 nmol/L) and vitamin
D insufficiency as 25-OHD levels between 10–20 ng/ml
(equivalent to 25–50 nmol/L). A serum level of greater
than 20 ng/ml (equivalent to >50 nmol/L) is considered
optimal [29].
Cardiovascular risk factors
Anthropometric measures were recorded as described in
Gaughran et al., 2013 [20]. Additionally, we measured
high sensitivity serum C-reactive protein (HS-CRP) levels.
All bloods were fasting. A participant was classified as
having a particular cardiovascular risk factor if the meas-
ure met the World Health Organisation reference stand-
ard for obesity or otherwise met the cut-off used in the
diagnosis of metabolic syndrome (MetS) by the Inter-
national Diabetes Federation [30]. Normal weight, over-
weight, and obesity therefore were defined as a BMI less
than 25 kg/m2, 25 to 29.9 kg/m2, and 30 kg/m2 or higher
respectively; central obesity as a waist circumference
>94 cm in males and >80 cm in females; hypertension as a
systolic BP greater than or equal to 130 mmHg or diastolic
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greater than or equal to 85 mmHg; dyslipidaemia as hav-
ing a serum total cholesterol >5 mmol/L; or a LDL
>3 mmol/L; and/or an HDL of <1.03 mmol/L in males
and <1.29 mmol/L for females; and/or a serum triglyceride
level >1.7 mmol/L; type 2 diabetes mellitus (DM) (fasting
serum glucose >7.0 mmol/L and/or a HbA1c > 6.5 %).
Data analysis
Statistical analysis was performed using the IBM Statis-
tical Package for Social Sciences Statistics for Windows,
Version 20.0 (Armonk, NY: IBM Corp). Variables were
reported as percentages or means ± standard deviation
(SD) as appropriate. Data analysis was performed using
correlation coefficients, ×2-tests, student-t tests and ana-
lysis of variance (ANOVA) for parametric data where
appropriate.
The primary analysis established the prevalence of
vitamin D deficiency in the population. In the secondary
analysis we examined the relationships between serum
25-OHD levels and clinical details, including associa-
tions between 25-OHD levels and mental health status
and with cardiometabolic risk factors, using correlations
and ANOVA testing. Partial correlations between serum
25-OHD levels and variables of interest were examined
using Pearson’s coefficients controlling for age, gender,
ethnicity and season of 25-OHD blood sampling. An
ANOVA was conducted to assess for significant differ-
ences between mean levels of serum 25-OHD levels
within groups. Post hoc analyses using the Tukey post
hoc criterion for significance was conducted where
ANOVA demonstrated significant differences between
the group means. All statistical tests were two-sided and
the α- level for statistical significance was 0.05.
Confounding factors
The following proposed confounding factors were evalu-
ated: gender, age, and ethnicity, smoking status; alcohol
use; body mass index. We used the season of blood sam-
pling as a proxy for sunlight irradiation, as it is a factor
which will affect the duration and intensity of sunlight
exposure. We defined the seasons as follows: summer-
June to August; Autumn-September-November; Winter-
December to February; Spring–March-May.
Ethical approval for this study was obtained from The
Joint South London and Maudsley and The Institute of
Psychiatry NHS Research Ethics Committee. Ethical ap-
proval was granted on 17th July 2009 (REC Ref no. 09/
H080/41). All participants provided informed written
consent.
Results
Vitamin D levels were available for 324 patients (59.6 %
male) with a mean age of 43.6 (SD = 10.1) years (see
Table 1). Participants lived in regions between latitude
52.8 °N and latitude 51.4 °N, with 280 living in urban
and 44 in rural settings.
Vitamin D levels and deficiency
The mean 25-OHD serum level was 12.4 (SD 7.3) ng/ml
(range 4.0−51.7 ng/ml). Almost half of the sample
(48.8 %, n = 158) were deficient in vitamin D while only
13.9 % (n = 45) had sufficient vitamin D.
Vitamin D levels and clinical and demographic
characteristics
The associations between 25-OHD levels and demo-
graphic, and clinical features are shown in Table 1.
Briefly, mean 25-OHD levels were significantly lower in
those of black African/black Caribbean ethnicity than in
those of white ethnicity. Serum 25-OHD levels did not
differ between males (mean 12.2 ng/ml (SD = 7.0) and
females (mean 12.6 ng/ml (SD = 7.8) (t = −0.511, p =
0.610)); nor between urban (mean 12.4 (SD 7.5) ng/ml
and rural settings (mean 12.5 (SD 6.0) (p = 0.907). There
was no significant relationship between serum 25-OHD
levels and duration of illness (r = −0.015, p = 0.808).
Vitamin D levels and mental state
Serum 25-OHD levels were not significantly associated
with PANNS total scores (r = −0.106, p = 0.058); PANSS
positive scores (r = −062, p = 0.272); PANSS negative
scores (r = −0.103, p = 0.066); GAF score (r = −062, p =
0.270); or MADRS score (r = −087, p = 0.117).
Vitamin D levels and cardiovascular disease risk factors
Associations between cardiovascular risk factors and
serum 25-OHD levels are shown in Table 2. After ad-
justment for age, gender and ethnicity and season of
sampling, serum 25-OHD levels were significantly
negatively correlated with waist circumference (r =
−0.220, p < 0.002), BMI (r = −0.163, p = 0.022), triglycer-
ides (r = −0.160, p = 0.024), total cholesterol (r = −0.144,
p = 0.043), fasting glucose (r = −0.191, p = 0.007), HbA1c
(r = −0.183, p = 0.01), and CRP (r = −0.211, p = 0.003).
Those with vitamin D deficiency (serum 25-OHD levels
<10 ng/ml) had mean CRP levels of 7.8 (SD 10.4) mg/L,
significantly higher than those who were not vitamin D
deficient (serum CRP of 3.9 (SD 4.3) mg/L (t = 3.789, p <
0.001). Further serum 25-OHD levels were significantly
negatively correlated with hypertension (r = −0.180, p =
0.011).
The prevalence of metabolic syndrome (as defined
by the International Diabetes Federation [30]) in asso-
ciation with increasing quartiles of serum 25-OHD
was investigated. Participants within the highest quar-
tile of vitamin D (mean serum 25-OHD level 22.8 ng/
ml (SD = 6.3; range 16.5−51.7 ng/ml) had the lowest
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Table 1 Clinical/demographic characteristics and differences in mean vitamin D by season of sampling, age categories, ethnicity & diagnoses
Total (n = 324) Male (n = 193) Female (n = 131)
Mean age (SD) 43.8 (10.1) 43.2 (10.1) 44.7 (10.2)
Mean Duration of illness (SD) 16.5 (10.4) 17.1 (10.5) 15.6 (10.4)
Mean Vitamin D levels 12.4 (7.3) 12.2 (7.0) 12.6 (7.8)
Mean 25-OHD levels (ng/ml) ± SD T df P Value
Age categories Age ≤ 44 (n = 172) Age > 44 (n = 152)
12.1 ± 7.1 12.7 ± 7.5 −0.724 322 0.663
Diagnosis Non affective psychosis (i.e. Schizophrenia)
(n = 218)
Affective psychosis (Schizoaffective disorder,
BPAD, psychotic depression) (n = 96)
11.5 ± 6.7 14.3 ± 8.1 3.099 312 0.061
Mean 25-OHD levels (ng/ml) ± SD/Vitamin D deficiency % F df p Value
Season of sampling Autumn (n = 96)/38 % Winter (n = 70)/69 % Spring (n = 70)/60 % Summer (n = 88)/36 % 12.977 3 <0.001*
14.3 ± 7.31,2 9.4 ± 5.9 9.8 ± 4.82 14.7 ± 8.51,2
Ethnicity Black (n = 104) White (n = 183) Asian (n = 12) Mixed/Others (n = 24) 2.707 3 0.008*
10.6 ± 5.93 13.5 ± 8.13 10.7 ± 8.4 12.4 ± 4.9
Student-t tests and analysis of variance (ANOVA) were conducted to assess for differences in serum 25-OHD between groups. The *values represent the significant difference with p <0.05
1,2Mean serum 25-hydroxyvitamin D (25-OHD) levels were significantly decreased in those who had blood sampling in Winter compared to Summer or Autumn (p < 0.001) and were significantly decreased in Spring
compared to Summer or Autumn (p < 0.001)
3Mean 25-OHD levels were significantly decreased in those of black ethnicity compared to those of white ethnicity (p = 0.002)
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prevalence of MetS (N = 73, 20.5 %) (see Fig. 1). Par-
ticipants within the first (N = 92, 39.1 % MetS), sec-
ond (N = 93, 48.3 % MetS) and third (N = 95, 43.15 %
MetS) lowest vitamin D quartiles were at 2.48 (OR
95 % CI 1.22 to 5.03), 3.62 (OR 95 % CI 1.80 to
7.28), 2.93 (OR 95 % CI 1.46 to 5.89) greater odds of
having MetS compared to participants within the
highest quartile of vitamin D.
Vitamin D levels and lifestyle factors
There was no significant difference between serum
25-OHD levels in current tobacco smokers (n = 197)
versus non-smokers (n = 127) (p = 0.821) nor any asso-
ciation between serum 25-OHD levels and alcohol
use as measured by the AUDIT (p = 0.455). The use
of vitamin supplements (n = 20) did not affect 25-
OHD levels (t = −0.712, p = 0.477).
Those engaging in low intensity physical activity over
the week prior to sampling (n = 137) had significantly
lower 25-OHD levels (mean =10.91 ng/ml (SD = 6.87)
than those who engaged in moderate or high intensity
physical activity (n = 187) (mean = 13.45 ng/ml (SD =
7.47) (t = −3.123, df =322, p = 0.002). There was a direct
relationship between serum 25-OHD levels and the
amount of hours spent outdoors (r = 0.140, p = 0.012).
Discussion
To our knowledge, this is the largest study to date inves-
tigating 25-OHD levels in community dwelling individ-
uals with established psychosis. Nearly half of our study
sample had vitamin D deficiency, more than in previ-
ously published studies of psychosis, for example the
26 % (n = 34) seen in a Norwegian study of outpatients
with psychosis [15]. As in the general population, black
Table 2 Significant bivariate and partial correlations between
serum levels of 25-Hydroxyvitamin D (25-OHD) and cardiometabolic
risk factors among patients with psychosis
Bivariate r for
25-OHD level
Partial r for
25-OHD level
Waist −0.188** −0.220**
BMI −0.149* −0.163*
Type 2 DM −0.147* −0.128
MetS −0.117* −0.151*
Fasting glucose −0.135* −0.191**
HbA1c −0.146** −0.183**
Serum triglyceride −0.133* −0.160*
Serum total cholesterol −0.128* −0.144*
Systolic blood pressure −0.084 −0.134
Diastolic blood pressure −0.151** −0.128
CRP level −0.206** −0.211**
Bivariate and partial correlations (r) between serum 25-OHD levels and
cardiometabolic risk factors were examined using Pearson’s coefficients,
with controlling for age, gender, ethnicity and season of 25-OHD blood
sampling. The *values represent the significant difference with p <0.05,
**with p < 0.01 and ***with p < 0.001
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Fig. 1 Prevalence of Metabolic Syndrome (MetS) according to Vitamin D quartile. footnote: First (VitD0), second (VitD1), third (VitD2) and fourth
(VitD3) quartiles with mean serum 25-OHD levels of 5.4 ng/ml (SD = 1.0), 8.6 ng/ml (SD = 0.94), 12.8 ng/ml (SD = 1.8), and 22.8 ng/ml (SD = 6.3),
and 25-OHD levels in each of VitD0, VitD1, VitD2 and VitD3 which ranged from 34.0−7.0 ng/ml, 7.0−10.2 ng/ml, 10.3−16.4 ng/ml and 16.5−51.7 ng/
ml. Logistic regression was performed to test the differences
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African or black Caribbean people with psychosis had
lower levels than their white counterparts. Moreover, we
have for the first time in a population with established
psychosis, identified that those with the highest levels of
vitamin D have a lower prevalence of MetS (20.5 %),
compared to those in the lowest (39.1 %), second
(48.3 %) and third quartile (43.1 %) of vitamin D (all p <
0.01). For the first time we have demonstrated that those
people with psychosis that engage in more moderate and
vigorous physical activity have significantly higher levels
of vitamin D (p = 0.002).
Vitamin D and cardiometabolic risk
Perhaps the most novel and significant finding within
this study is the relationships we observed between 25-
OHD levels and cardiovascular risk factors in psychotic
illnesses. We observed a clear inverse relationship be-
tween rising vitamin D levels and decreased MetS risk,
which has important implications given that MetS and
cardiovascular disease are highly prevalent [9, 10] and
leading causes of premature mortality [19]. Of interest,
we identified associations with hypertension and low 25-
OH levels. This is likely to be clinically important as in
the general population low 25-OHD levels are associated
with the risk of incident CVD and specifically hyperten-
sion [31]. Further, the inverse relationship between 25-
OHD levels and dyslipidaemia, previously demonstrated
in large general population samples, and replicated here,
is worthy of further exploration given the high risk of
cardiovascular morbidity in psychosis. The strongest
correlations with low 25-OHD levels were with factors
related to high body fat. This is consistent with findings
that those with increased adipose tissue stores (in which
vitamin D, being fat soluble, is stored), due to obesity,
have lower circulating vitamin D due to this increased
storage capacity [32]. The low 25-OHD levels could then
be a secondary manifestation of obesity.
Given these results, the questions that one could pose
is, would the supplementation of vitamin D in psychosis
prevent and/or ameliorate cardiovascular and metabolic
risk? This is a key question that needs addressing in fu-
ture work.
Raised levels of the inflammatory marker CRP, which
is pathogenic in the development of CVD, have been de-
scribed in both schizophrenia [33] and bipolar affective
disorder [34]. This is the largest study to identify an as-
sociation between raised CRP and vitamin D deficiency
in established psychosis, with a similar inverse relation-
ship between CRP and serum 25-OHD having been pre-
viously identified in schizophrenia patients in a case–
control study [14]. This is interesting in the context of
vitamin D’s known anti-inflammatory properties, espe-
cially given the recent resurgence of research into auto-
immunity and inflammation in psychosis. Clinical trials
have shown inconsistent results regarding the benefits of
vitamin D supplementation in reducing CRP levels in
the general population [35], but this may be worth fur-
ther examination in psychosis.
Another novel finding from this study is the associ-
ation between low vitamin D in established psychotic
disorders and decreased physical activity [15]. This fur-
ther adds to the notion that engaging people with psych-
osis may improve health outcomes, including vitamin D
status. The association between time spent outside and
higher serum 25-OHD levels provides support for select-
ive strategies to encourage increased outdoor activity in
people with psychosis –not only to boost vitamin D
levels but for all the other known health benefits. Vita-
min D levels were not appreciably higher in those taking
vitamin D supplements. This may support the notion
that most of these supplements contain much too low a
dose of vitamin D to have a meaningful effect on serum
levels [36], although there remains the possibility, not
tested, that supplements may have been prescribed be-
cause of an already suspected inadequate level or that
treatment non-adherence may have occurred.
The lack of a prospective study design means further
work is needed to answer the question of causality; how-
ever, in the meantime it is important that primary and
secondary health care professionals are aware of the high
rates of vitamin D deficiency in people with established
psychosis. This is particularly so, given that people with
psychotic illnesses residing in the geographical area
where this work was carried out, have a life span short-
ened by up to 18 years [37]. This reduced life expectancy
is largely due to cardiovascular disease, for which vita-
min D deficiency is a known risk factor in the general
population [31, 18]. It is also clinically noteworthy that
vitamin D deficiency may exacerbate the effects of lower
bone mineral density and increased osteoporosis seen in
psychosis [38, 39], particularly as osteoporosis is more
prevalent in black patients [40]. This may partially ac-
count for the fact that people with schizophrenia have
more fractures than the general population [41].
Comparison with other populations
Studies of inpatients with schizophrenia have reported
vitamin D deficiency rates of 11 %–26 % [1, 2]. A mean
25-OHD level of 29.0 ng/ml was observed in one in-
patient sample of 34 schizophrenia patients, much
higher than that in our UK sample [42]. Our vitamin D
deficiency prevalence of 50 % contrasts with that of an
epidemiological cohort (N =7437) of UK males, where
16 % had vitamin D deficiency (using the same defini-
tions) in the winter and spring (64 % in our study), fall-
ing to 3 % in the summer and autumn (36 % in our
study) [43]. In the 2004 UK National Health Survey,
14 % of men and 15 % of women were vitamin D
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deficient (using the same definitions) compared to of
48 % of males and 51 % of females in our study. This ex-
cess is highlighted when an aged-matched comparison is
used; for those aged 35–49 in the same study, the mean
25-OHD level was 48 nmol/L (equivalent to 19.2 ng/ml),
compared to the mean 25-OHD level of 12.1 ng/ml in
this age group in our study [44].
Similar to findings from a recent mini meta-analysis,
[45] we also observed that individuals with schizophre-
nia had a trend towards lower 25-OHD levels than those
with other psychotic disorders. However, since our num-
bers with diagnoses of schizoaffective disorder and bipo-
lar affective disorder are relatively small, it is difficult to
draw firm conclusions. We did not identify significant
correlations with clinical symptoms and 25-OHD levels,
but an inverse relationship between 25-OHD levels and
psychotic and depressive symptoms is the overall trend
in these analyses in keeping with expectations.
Strengths and limitations
The study is limited by its cross sectional design, mean-
ing that no inference on the directionality of the associ-
ation between vitamin D and psychotic disorders or
symptoms can be made. As such further replication in
large prospective cohorts would be valuable. We have
identified a higher prevalence of vitamin D deficiency in
established psychosis when compared to general popula-
tion samples, though comparisons are limited by an in-
ability to control for ethnicity and by the use of different
assay techniques. The use of automated immunoassays
to quantify 25-OHD levels may limit the generalisability
of the findings due to variable concordance between dif-
ferent mechanisms of 25-OHD measurement. In particu-
lar, immunoassays may underestimate true vitamin D
deficiency, as they can overestimate serum 25-OHD re-
sults at serum levels <8 ng/ml (<20 nmol/L) [46], which
could have potentially led to an underestimate of vita-
min D deficiency in this sample. Study strengths include
the large sample size, random sampling across multiple
sites, clinical diagnoses of schizophrenia and other
psychotic disorders, measures of clinical status and the
multi-ethnicity of the population, which should enhance
the study’s generalisability.
Conclusions
Because of the potential adverse effects of vitamin D de-
ficiency on the skeletal system and on cardiovascular
morbidity, the question of whether to recommend wide-
spread screening for vitamin D deficiency or routine
vitamin D supplementation arises. There is as yet no evi-
dence that Vitamin D supplementation will improve
psychotic symptoms, so the question should be looked
at in the light of general population guidelines. Evidence
is lacking here too, pending the results of large ongoing
RCTs [47] and clinical equipoise remains about the gen-
eral health benefits of routine population screening and
supplementation of vitamin D [48]. However, given the
extremely low levels of vitamin D seen in this vulnerable
population, large randomised trials, specifically in psych-
osis, are urgently needed to determine whether supple-
mentation with vitamin D is an effective means of
ameliorating mental health outcomes [49], boosting car-
diometabolic health and ultimately reducing mortality in
psychosis.
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